New treatment targeting tau protein for Alzheimer's disease
Acetylated Tau Immunotherapy for Alzheimer's Disease
['FUNDING_OTHER'] · AETON THERAPEUTICS, INC. · NIH-10820821
This study is working on a new treatment for Alzheimer's disease that uses special antibodies to target a harmful protein in the brain, with the hope of helping people with Alzheimer's feel better and protect their brain health.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | AETON THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (BURLINGAME, UNITED STATES) |
| Trial ID | NIH-10820821 on ClinicalTrials.gov |
What this research studies
This research focuses on developing an immunotherapy that targets acetylated tau protein, which is a key factor in the progression of Alzheimer's disease. The approach involves creating monoclonal antibodies that can bind to this modified tau protein, potentially reducing its harmful effects in the brain. By using mouse models, the researchers have shown promising results in protecting brain regions affected by Alzheimer's, such as the hippocampus. The goal is to translate these findings into a treatment that could improve the lives of patients suffering from Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 65 and older who are diagnosed with Alzheimer's disease.
Not a fit: Patients with early-stage Alzheimer's or those under 65 years of age may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that slows down or alters the progression of Alzheimer's disease.
How similar studies have performed: Other research targeting tau proteins has shown promise, indicating that this approach could be a viable treatment strategy.
Where this research is happening
BURLINGAME, UNITED STATES
- AETON THERAPEUTICS, INC. — BURLINGAME, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SINHA, ANJANA — AETON THERAPEUTICS, INC.
- Study coordinator: SINHA, ANJANA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.